Literature DB >> 26899237

Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.

Yun-Tzai C Lee1, Shang-Te D Hsu2.   

Abstract

Parkinson's disease (PD) is one of the most common progressive neurodegenerative disorders in modern society. The disease involves many genetic risk factors as well as a sporadic pathogenesis that is age- and environment-dependent. Of particular interest is the formation of intra-neural fibrillar aggregates, namely Lewy bodies (LBs), the histological hallmark of PD, which results from aberrant protein homeostasis or misfolding that results in neurotoxicity. A better understanding of the molecular mechanism and composition of these cellular inclusions will help shed light on the progression of misfolding-associated neurodegenerative disorders. Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is found to co-aggregate with α-synuclein (αS), the major component of LBs. Several familial mutations of UCH-L1, namely p.Ile93Met (p.I93M), p.Glu7Ala (p.E7A), and p.Ser18Tyr (p.S18Y), are associated with PD and other neurodegenerative disorders. Here, we review recent progress and recapitulate the impact of PD-associated mutations of UCH-L1 in the context of their biological functions gleaned from biochemical and biophysical studies. Finally, we summarize the effect of these genetic mutations and post-translational modifications on the association of UCHL1 and PD in terms of loss of cellular functions or gain of cellular toxicity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Lewy bodies; Parkinson’s disease; UCH-L1; misfolding; ubiquitin; α-synuclein

Mesh:

Substances:

Year:  2017        PMID: 26899237     DOI: 10.2174/1389203717666160217143721

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  6 in total

1.  C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes.

Authors:  E Kobayashi; M Aga; S Kondo; C Whitehurst; T Yoshizaki; J S Pagano; J Shackelford
Journal:  mSphere       Date:  2018-02-07       Impact factor: 4.389

2.  Entropic stabilization of a deubiquitinase provides conformational plasticity and slow unfolding kinetics beneficial for functioning on the proteasome.

Authors:  Yun-Tzai Cloud Lee; Chia-Yun Chang; Szu-Yu Chen; Yun-Ru Pan; Meng-Ru Ho; Shang-Te Danny Hsu
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

Review 3.  Deubiquitinating Enzymes Related to Autophagy: New Therapeutic Opportunities?

Authors:  Anne-Claire Jacomin; Emmanuel Taillebourg; Marie-Odile Fauvarque
Journal:  Cells       Date:  2018-08-19       Impact factor: 6.600

4.  Diverse proteins aggregate in mild cognitive impairment and Alzheimer's disease brain.

Authors:  Devin Kepchia; Ling Huang; Richard Dargusch; Robert A Rissman; Maxim N Shokhirev; Wolfgang Fischer; David Schubert
Journal:  Alzheimers Res Ther       Date:  2020-06-19       Impact factor: 6.982

Review 5.  Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury.

Authors:  Kevin K W Wang; Firas H Kobeissy; Zaynab Shakkour; J Adrian Tyndall
Journal:  Acute Med Surg       Date:  2021-01-19

Review 6.  Atypical Ubiquitination and Parkinson's Disease.

Authors:  Olga Buneeva; Alexei Medvedev
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.